By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
.
A device called a bone stimulator produces an electric current with the goal of promoting bone development. It makes use of electromagnetic pulses or ultrasonic waves. Bone stimulator therapy must be administered consistently to be effective. Bone stimulators can be externally placed on the afflicted bone or surgically implanted there.
Both pulsed ultrasonic energy and low-level pulsed electromagnetic fields are produced by bone development stimulators. According to hypothesis, these energy fields encourage bone growth by aiding in tissue healing and promoting cell growth and maturity.
In order to stimulate bone formation, devices that generate either pulsed ultrasonic energy or a low-level pulsed electromagnetic field are used. These energy fields are thought to encourage bone growth by aiding in tissue healing and promoting cell creation and maturation.
The Global Ultrasound Bone Healing System market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
With the help of ultrasound technology, the EXOGEN Ultrasound Bone Healing System speeds up your body’s normal fracture healing processes. repairing fractures that do not mend naturally.
Bioventus has a clinical development program me called BONES (Bioventus Observational Non-interventional EXOGEN Studies). Three direct-to-patient observational, non-interventional trials using the EXOGEN ultrasound bone healing system are part of the BONES study series.
EXOGEN uses low-intensity pulsed ultrasound (LIPUS), a safe and efficient technique, to aid in promoting the body’s normal bone repair process.
will compare the incidence of fracture non unions in patients utilizing EXOGEN with patients from a national health insurance claims database who received standard of care alone. The studies will include long and small bones of upper and lower extremities and the unique design of BONES was discussed with FDA during its development.
Its primary endpoint is defined as the ability of EXOGEN to mitigate the risk of a fracture progressing to nonunion in the presence of known risk factors.
